Merck and Vertex hep C protease data reveals contrasting market strategies
This article was originally published in Scrip
While new levels of details on the clinical performance of the two near-market hepatitis C protease inhibitors, Merck’s boceprevir and Vertex/Tibotec’s telaprevir, show that both compounds are likely to make a significant difference to patients, it is also becoming clear that the two compounds are being positioned very differently in the market. While Merck seems to be focused on specialist care with the company looking to identify those patients who are likely to respond best to boceprevir, Vertex/Tibotec is holding up telaprevir as a one-size-fits-all solution applicable across the board in community care.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.